Schrödinger, Inc.

NasdaqGS:SDGR Stock Report

Market Cap: US$1.7b

Schrödinger Past Earnings Performance

Past criteria checks 0/6

Schrödinger's earnings have been declining at an average annual rate of -24.8%, while the Healthcare Services industry saw earnings growing at 20% annually. Revenues have been growing at an average rate of 17% per year.

Key information

-24.82%

Earnings growth rate

-2.28%

EPS growth rate

Healthcare Services Industry Growth1.72%
Revenue growth rate17.03%
Return on equity-51.46%
Net Margin-83.39%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Schrödinger, Inc. (NASDAQ:SDGR) Looks Just Right With A 33% Price Jump

Apr 28
Schrödinger, Inc. (NASDAQ:SDGR) Looks Just Right With A 33% Price Jump

An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 46% Undervalued

Mar 27
An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 46% Undervalued
author-image

Partnerships With Novartis And Lilly Will Strengthen Future Prospects

Expansion in software and partnerships with pharmaceutical giants is expected to boost revenue and margins significantly.

Schrödinger: Still Waiting On A Catalyst

Mar 02

What Does Schrödinger, Inc.'s (NASDAQ:SDGR) Share Price Indicate?

Feb 28
What Does Schrödinger, Inc.'s (NASDAQ:SDGR) Share Price Indicate?

Schrödinger: An Interesting Investment With Immense Potential

Feb 15

Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 25% Higher

Jan 25
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 25% Higher

Companies Like Schrödinger (NASDAQ:SDGR) Are In A Position To Invest In Growth

Jan 06
Companies Like Schrödinger (NASDAQ:SDGR) Are In A Position To Invest In Growth

Schrödinger: Positive Signs Despite The Share Price Decline

Nov 21

Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher

Nov 13
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher

Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty

Oct 17

Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues

Sep 27
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues

Schrodinger: More Drug Discovery Validation

Aug 06

Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation

Aug 05
Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Jun 12
We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Schrödinger: More Pharmaceutical Than Software

May 07

Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

May 02
Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Mar 01
Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024

Mar 01

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Feb 28
Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%

Feb 01
The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%

Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable

Dec 18
Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Sep 28
Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Jul 01
Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Schrödinger: Q2 Earnings Supports Growth Narrative

Aug 26

Schrödinger appoints Dr. Geoffrey Porges as finance chief

Aug 18

Revenue & Expenses Breakdown

How Schrödinger makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:SDGR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 25230-192140197
31 Dec 24208-187140202
30 Sep 24193-178140204
30 Jun 24201-201138200
31 Mar 24188-143137192
31 Dec 2321741136182
30 Sep 2319944133165
30 Jun 2319466131151
31 Mar 2319714128139
31 Dec 22181-149121126
30 Sep 22170-153112117
30 Jun 22163-148105107
31 Mar 22154-1359697
31 Dec 21138-1008691
30 Sep 21125-818183
30 Jun 21121-427277
31 Mar 21114-116572
31 Dec 20108-246065
30 Sep 20101-205458
30 Jun 2095-355252
31 Mar 2091-335245
31 Dec 1986-254839
30 Sep 1977-244637
30 Jun 1970-244336
31 Mar 1969-293835
31 Dec 1867-283635
31 Dec 1756-173128

Quality Earnings: SDGR is currently unprofitable.

Growing Profit Margin: SDGR is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SDGR is unprofitable, and losses have increased over the past 5 years at a rate of 24.8% per year.

Accelerating Growth: Unable to compare SDGR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SDGR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (7.3%).

Return on Equity

High ROE: SDGR has a negative Return on Equity (-51.46%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 08:53
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Schrödinger, Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gaurav GoparajuBerenberg
Clarence PowellBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research